Skip to main content

Table 2 Antimicrobial susceptibilities of Proteus mirabilis by specimen types and patient locations

From: Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program

Antimicrobial agentsa

Specimen typesb

Patient locations

 

Urine (n = 571)

Pus/abscess (n = 233)

Blood (n = 158)

Sputum (n = 133)

ICU (n = 134)

Non-ICU (n = 618)

Outpatients (n = 401)

β-lactams:

       

  Amoxicillin/CAc

83.2

87.1

88.9

76.9

72.3 d

83.9

88.9

  Ampicillin

33.1

36.2

44.4

25.3

33.0

31.7

40.2

  Cefazolin_2009

74.3

73.6

77.8

50.6

58.5

69.2

81.6

  Cefazolin

1.2

1.2

0

0

1.1

0.7

1.2

  Cefazolin_UTIe

81.2

-

-

-

64.7

79.5

86.5

  Cefuroxime

86.9

91.4

90

80.2

78.7

86.9

92.0

  Cefotaxime

85.6

89.2

84.8

80.3

80.6

84.6

89.3

  Ceftazidime

98.1

97.9

95.6

94.9

96.3

97.2

97.5

  Cefoxitin

94.1

96.9

94.4

94.5

91.5

95.1

96.2

  Cefepimef

97.0

98.3

99.4

95.6

95.5

97.1

98.5

  Imipenem_2009

100

100

100

100

99.3

100

100

  Imipenem

34.7

16.1

56.6

43.8

53.0

50.2

53.8

  Piperacillin

41.4

51.2

47.8

29.7

41.5

38.2

52.7

Non β-lactams:

       

  Amikacin

90.5

93.6

87.3

84.7

85.1

89.8

92

  Gentamicin

59.5

63.5

58.9

35.8

52.2

53.9

65.8

  Ciprofloxacin

69.2

70.8

67.1

64.2

62.7

66.5

74.6

  TMP/SMX (SXT)c

33.1

40.3

34.8

24.8

35.1

31.9

37.4

  1. aSusceptibility results are based on the current CLSI breakpoints [19]. For cefazolin and imipenem, results of the 2009 CLSI criteria are also shown for comparison [25]. Other agents with overall susceptibility >99% (aztreonam, ertapenem, meropenem) are not shown.
  2. bData on miscellaneous other specimen types (n = 63) are not shown.
  3. cAmox/CA, Amoxacillin/clavulanic acid; TMP/SMX (SXT), trimethoprim/sulfamethoxazole.
  4. dItalicized, significant difference in susceptibility rate compared to other subgroups.
  5. eResult of urine isolates are shown using the 2014 UTI breakpoints [19].
  6. fCefepime results include SDD (susceptible dose dependent) category.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us